ABSTRACT
Introduction: Follicular helper T cells are essential for helping in the maturation of B cells and the production of neutralizing antibodies (NAbs) during primary viral infections. However, their role during recall responses is unclear. Here, we used hepatitis C virus (HCV) reinfection in humans as a model to study the recall collaborative interaction between circulating CD4 T follicular helper cells (cTfh) and memory B cells (MBCs) leading to the generation of NAbs. Methods: We evaluated this interaction longitudinally in subjects who have spontaneously resolved primary HCV infection during a subsequent reinfection episode that resulted in either another spontaneous resolution (SR/SR, n = 14) or chronic infection (SR/CI, n = 8). Results: Both groups exhibited virus-specific memory T cells that expanded upon reinfection. However, early expansion of activated cTfh (CD4+CXCR5+PD-1+ICOS+FoxP3-) occurred in SR/SR only. The frequency of activated cTfh negatively correlated with time post-infection. Concomitantly, NAbs and HCV-specific MBCs (CD19+CD27+IgM-E2-Tet+) peaked during the early acute phase in SR/SR but not in SR/CI. Finally, the frequency of the activated cTfh1 (CXCR3+CCR6-) subset correlated with the neutralization breadth and potency of NAbs. Conclusion: These results underscore a key role for early activation of cTfh1 cells in helping antigen-specific B cells to produce NAbs that mediate the clearance of HCV reinfection.
Subject(s)
Hepacivirus , Hepatitis C , Memory B Cells , Reinfection , T Follicular Helper Cells , Humans , Hepacivirus/immunology , T Follicular Helper Cells/immunology , Male , Female , Hepatitis C/immunology , Hepatitis C/virology , Memory B Cells/immunology , Adult , Middle Aged , Reinfection/immunology , Reinfection/virology , Antibodies, Neutralizing/immunology , Antibodies, Neutralizing/blood , Immunologic Memory , Hepatitis C Antibodies/immunology , Hepatitis C Antibodies/blood , Hepatitis C, Chronic/immunology , Hepatitis C, Chronic/virology , Lymphocyte Activation/immunologyABSTRACT
The introduction of direct-acting antivirals (DAAs) has revolutionized hepatitis C treatment. Short courses of treatment with these drugs are highly beneficial to patients, eliminating hepatitis C virus (HCV) without adverse effects. However, this outstanding success is tempered by the continuing difficulty of eradicating the virus worldwide. Thus, access to an effective vaccine against HCV is strongly needed to reduce the burden of the disease and contribute to the elimination of viral hepatitis. The recent failure of a T-cell vaccine based on the use of viral vectors expressing the HCV non-structural protein sequences to prevent chronic hepatitis C in drug users has pointed out that the induction of neutralizing antibodies (NAbs) will be essential in future vaccine candidates. To induce NAbs, vaccines must contain the main target of this type of antibody, the HCV envelope glycoproteins (E1 and E2). In this review, we summarize the structural regions in E1 and E2 proteins that are targeted by NAbs and how these proteins are presented in the vaccine candidates currently under development.
Subject(s)
Hepatitis C, Chronic , Hepatitis C , Viral Hepatitis Vaccines , Humans , Antibodies, Neutralizing , Viral Envelope Proteins/metabolism , Antiviral Agents/metabolism , Hepatitis C, Chronic/prevention & control , Hepacivirus , Hepatitis C AntibodiesABSTRACT
Hepatitis C is a major threat to public health for which an effective treatment is available, but a prophylactic vaccine is still needed to control this disease. We designed a vaccine based on chimeric HBV-HCV envelope proteins forming subviral particles (SVPs) that induce neutralizing antibodies against HCV in vitro. Here, we aimed to increase the neutralizing potential of those antibodies, by using HBV-HCV SVPs bearing apolipoprotein E (apoE). These particles were produced by cultured stable mammalian cell clones, purified and characterized. We found that apoE was able to interact with both chimeric HBV-HCV (E1-S and E2-S) proteins, and with the wild-type HBV S protein. ApoE was also detected on the surface of purified SVPs and improved the folding of HCV envelope proteins, but its presence lowered the incorporation of E2-S protein. Immunization of New Zealand rabbits resulted in similar anti-S responses for all rabbits, whereas anti-E1/-E2 antibody titers varied according to the presence or absence of apoE. Regarding the neutralizing potential of these anti-E1/-E2 antibodies, it was higher in rabbits immunized with apoE-bearing particles. In conclusion, the association of apoE with HCV envelope proteins may be a good strategy for improving HCV vaccines based on viral envelope proteins.
Subject(s)
Apolipoproteins E/administration & dosage , Apolipoproteins E/immunology , Hepacivirus/immunology , Hepatitis B virus/immunology , Viral Hepatitis Vaccines/administration & dosage , Viral Hepatitis Vaccines/immunology , Animals , Antibodies, Neutralizing/biosynthesis , Antibodies, Neutralizing/blood , Antigen Presentation/immunology , Cell Line , Female , Hepatitis C/immunology , Hepatitis C/prevention & control , Hepatitis C Antibodies/biosynthesis , Hepatitis C Antibodies/blood , Humans , Immune Evasion , Rabbits , Recombinant Fusion Proteins/administration & dosage , Recombinant Fusion Proteins/immunology , Viral Envelope Proteins/administration & dosage , Viral Envelope Proteins/immunologyABSTRACT
The development of a safe, effective and affordable prophylactic vaccine against hepatitis C virus (HCV) remains a medical priority. Hepatitis B-C subviral envelope particles, which could be produced by industrial procedures adapted from those established for the hepatitis B virus vaccine, appear promising for use for this purpose. The prototype HBV-HCV bivalent vaccine-bearing genotype 1a HCV envelopes can induce neutralizing antibodies against this genotype, but is less effective against other genotypes. We show here, in a small animal model, that the use of a set of vaccine particles harbouring envelopes from different HCV genotypes in various association strategies can induce broad neutralizing protection or an optimized protection against a particular genotype prevalent in a given region, such as genotype 4 in Egypt. This vaccine could help to control the hepatitis C epidemic worldwide.